Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events

New Research Casts Doubt on Monkeys as Drug Testing Model

publication date: Nov 19, 2014
 | 
author/source: FRAME

FRAME is calling for increased investment in cell-based and computer methods of drug testing following new research that demonstrates serious flaws in an animal model.

frame logoCynomolgus monkeys are considered a valuable species for drug testing because of their size and their relatively close genetic parallels with humans. Now new experiments to investigate how the liver handles the commonly-used painkiller paracetamol have revealed that cynomolgus monkeys are resistant to doses that would be fatal in humans.

The findings cast serious doubt on the use of these monkeys as an animal model for drug testing. The ability of human and monkey livers to cope with high paracetamol doses is very different so it is not possible to say reliably that these monkeys are suitable for testing other drugs.

Paracetamol overdose, either accidental or intentional, is the main cause of acute liver failure in the UK and the USA, often proving fatal. It has been assumed that, because of their similarity to humans, non-human primates like the cynomolgus monkey would react in a similar way to overdosing.

But it appears the monkeys possess a high capacity detoxification system within the liver, which works at much lower capacity in humans. Therefore cynomolgous monkeys are able to eliminate very high paracetamol doses efficiently and safely, but humans cannot.

FRAME Scientific Director Dr Gerry Kenna is now calling for more time and money to be invested in cell-based and computer models that would be more reliable than using non-human primates.

“This research highlights an important difference between cynomolgus monkeys and humans, which limits the value of this species for evaluation of human drug safety.

“Increasing use of non-human primates in safety testing of drug candidates is ethically undesirable. In view of the substantial cost of such studies, it can also be expected to increase markedly the cost of drug development. FRAME believes such studies should be considered only if they can be shown to be scientifically justifiable and there are no valid alternatives.

“Substantial progress is already being made in the development of in vitro and in silico methods which focus on human biology and human cell systems. It is more sensible to put new effort into them than to pursue animal models that have substantial flaws.”


more about frame


 

 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners